This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Pfizer Inc.

Drug Names(s): pantoprazole sodium, Protium, Somac (Europe), Pantecta Control (Europe)

Description: Protonix is an acid suppressant indicated for the short-term treatment (up to eight weeks) in the healing and symptomatic relief of erosive esophagitis associated with GERD.

Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours.

Deal Structure: Pfizer no longer reports revenues for Protonix as of Q4 2011.

Protonix was developed by Byk Gulden, which was later renamed Altana AG. On January 1, 2007, Altana Pharma AG became part of Nycomed following its acquisition.

Protonix is marketed in the U.S. by Wyeth Pharmaceuticals.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.

In May 2011, Takeda Pharmaceutical and Nycomed A/S jointly announced that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the company for 9.6 billion Euro on a cash-free, debt-free basis. The purchase would exclude Nycomed's U.S. dermatology business. The acquisition closed in September 2011.

Partners: Takeda Pharmaceutical Company Ltd

Protonix News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug